Patients with TD del(5q)-MDS demonstrate unique sensitivity to lenalidomide through a mechanism of synthetic lethality involving the haploinsufficiency of CSNK1A1 (encoding CK1α), a serine/threonine kinase in the common deleted region of chromosome 5q. Here, CSNK1A1 is linked to myelodysplastic syndrome.